Annual at-home stool test may be as effective as colonoscopy, study finds

This version of Annual Stool Test May Be Effective Colonoscopy Study Finds N975871 - Health and Medicine | NBC News Clone was adapted by NBC News Clone to help readers digest key facts more efficiently.

The stool test is cheaper and less invasive, experts say.
Image: Colonoscopy
At least 35 percent of people who should receive a colonoscopy don't get the procedure. Klaus Rose / ullstein bild via Getty Images

When it comes to colon cancer screening, an annual stool test may be as effective as colonoscopy for people who don’t have risk factors for the disease, a new study suggests.

Researchers analyzed data from 31 studies that included more than 120,000 average risk patients who had a stool test and then a colonoscopy. They determined that the fecal immunochemical test — or FIT — is sufficient to screen for colon cancer, according to the report published Monday in the Annals of Internal Medicine.

The FIT is designed to detect the protein hemoglobin, which is found in red blood cells. People who test positive with the FIT need to get a colonoscopy to determine whether they have cancer or pre-cancerous lesions. But those who test negative only need to keep getting the FIT each year to make sure they don’t develop colon cancer.

“This non-invasive test for colon cancer screening is available for average risk people," said the study’s lead author, gastroenterologist Dr. Thomas Imperiale, an investigator at the Regenstrief Institute in Indianapolis. "They should discuss with their providers whether it is appropriate for them.”

According to Imperiale, average risk means a person has:

  • no family history of colorectal cancer.
  • no personal history of inflammatory bowel disease.
  • no previous colon cancer or detected pre-cancerous polyps.

FIT is done at home by the patient and sent to a lab for evaluation.

The one downside to the at-home stool test is that it needs to be done yearly. But if used each year, the test is good enough to catch the vast majority of cancers, Imperiale said.

Switching to the FIT from colonoscopy for average risk patients without symptoms would bring colon cancer screening more in line with other cancer screens, such as mammography and PAP smears because, like them, it’s non-invasive, Imperiale said.

Though rare, colonoscopy can result in serious complications, such as a perforation of the colon, which occurs in about one in 1,000 cases, Imperiale said. Performing the FIT comes with very little risk.

Many patients experience fear and anxiety before undergoing colonoscopy, which may result in negative experiences. Some doctors believe that having FIT as an option might result in more people getting screened for colon cancer. Currently, 35 percent of people who should receive colonoscopies don't, the researchers noted.

FIT may also be a better option for screening people under age 50, the currently recommended age for colonoscopy. Recent studies have shown that colon cancer is striking younger and younger people and in response, the American Cancer Society has suggested lowering the age for a first colonoscopy to 45.

Despite that recommendation, it’s unlikely that any insurer will pay for a colonoscopy for younger patients, Imperiale said. For those patients, “using FIT to screen makes sense: it is zero risk from the test itself, is non-invasive, inexpensive, and will detect at least three of four cancers in the first application,” he added.

FIT is an excellent option for colon cancer screening only if it is performed consistently on a yearly basis.

In the study, Imperiale and his colleagues determined that when the FIT was set to be more sensitive, the test caught 95 percent of cancers, but resulted in 10 percent false positives. At a less sensitive setting, the FIT caught 75 percent of cancers but had just 5 percent false positives.

But, by doing the test every year, things improve dramatically, bringing the detection rate after just two years very close to that of the more sensitive setting, Imperiale said

Experts cautioned that while the FIT was less invasive, patients might not follow recommendations to get tested each year.

“FIT is an excellent option for colon cancer screening only if it is performed consistently on a yearly basis,” said Dr. Felice Schnoll-Sussman, a gastroenterologist at NewYork-Presbyterian Hospital and Weill Cornell Medicine. “Colon cancer screening and its impact on decreasing rates of colon cancer is a preventative health success story, although we have a way to go to increase rates to our previous desired goal of 80 percent screened in the U.S. by 2018.”

FIT has the possibility to increase screening rates, “so long as we create the infrastructure to do so in a high-quality way,” Schnoll-Sussman said in an email.

Dr. Robert Schoen is also concerned that patients won’t follow through with testing yearly, but it still may be more efficient than getting a colonoscopy every ten years.

“We know that when we do a colonoscopy we won’t find anything in 60 percent or so of cases,” said Schoen, a professor of medicine and epidemiology and chief of gastroenterology at the University of Pittsburgh Medical Center. “That’s not very efficient.”

FIT seems to be working in countries like the Netherlands, Spain and France, Schoen said.

“They are all doing centralized FIT screening,” he added. “It’s a lot cheaper and still a very effective means of screening and that’s a good thing.”

AdBlock Detected!
Please disable it to support our content.
×

Related Articles

Donald Trump Presidency Updates - Politics and Government | NBC News Clone | Joe Biden Campaign News - Politics and Government | NBC News Clone | Kamala Harris Vp Announcement - Politics and Government | NBC News Clone | Trump Indictment Latest - Politics and Government | NBC News Clone | Election Results Live - Politics and Government | NBC News Clone | Swing States Polling - Politics and Government | NBC News Clone | Debate Highlights - Politics and Government | NBC News Clone | Budget Approval 2025 - Politics and Government | NBC News Clone | Abortion Ruling - Politics and Government | NBC News Clone | Us China Relations - Politics and Government | NBC News Clone | Inflation Rates 2025 Analysis - Business and Economy | NBC News Clone | Federal Reserve Interest Rates - Business and Economy | NBC News Clone | Stock Market Today - Business and Economy | NBC News Clone | Recession Prediction 2025 - Business and Economy | NBC News Clone | Jobs Report Unemployment - Business and Economy | NBC News Clone | Ai Stock Surge - Business and Economy | NBC News Clone | Housing Market Crash - Business and Economy | NBC News Clone | Oil Prices Update - Business and Economy | NBC News Clone | Amazon Prime Sales - Business and Economy | NBC News Clone | Bitcoin Etf Approval - Business and Economy | NBC News Clone | Latest Vaccine Developments - Health and Medicine | NBC News Clone | Covid Variants Update - Health and Medicine | NBC News Clone | Boosters New Guidelines - Health and Medicine | NBC News Clone | Anxiety Depression Treatment - Health and Medicine | NBC News Clone | Longevity Research - Health and Medicine | NBC News Clone | Diet Trends 2025 - Health and Medicine | NBC News Clone | Workout Routines - Health and Medicine | NBC News Clone | Fda Approvals 2025 - Health and Medicine | NBC News Clone | Ukraine Russia Conflict Updates - World News | NBC News Clone | Israel Palestine War News - World News | NBC News Clone | China Taiwan Tensions - World News | NBC News Clone | Middle East Peace Talks - World News | NBC News Clone | European Union Politics - World News | NBC News Clone | Development News - World News | NBC News Clone | North Korea Missile Test - World News | NBC News Clone | Brazil Election - World News | NBC News Clone | Openai Chatgpt News - Technology and Innovation | NBC News Clone | Google Bard Ai - Technology and Innovation | NBC News Clone | Ai Regulation Laws - Technology and Innovation | NBC News Clone | Tiktok Ban Update - Technology and Innovation | NBC News Clone | Data Breaches 2025 - Technology and Innovation | NBC News Clone | Iphone 16 Release - Technology and Innovation | NBC News Clone | Nasa Mars Mission - Technology and Innovation | NBC News Clone | Web3 Developments - Technology and Innovation | NBC News Clone | 2024 Paris Games Highlights - Sports and Recreation | NBC News Clone | Super Bowl 2025 Preview - Sports and Recreation | NBC News Clone | Nba Playoffs 2025 - Sports and Recreation | NBC News Clone | Champions League Finals - Sports and Recreation | NBC News Clone | World Series 2025 - Sports and Recreation | NBC News Clone | Masters Tournament 2025 - Sports and Recreation | NBC News Clone | Extreme Weather Events - Weather and Climate | NBC News Clone | Hurricane Season 2025 - Weather and Climate | NBC News Clone | Global Warming Report - Weather and Climate | NBC News Clone | Weekly Weather Update - Weather and Climate | NBC News Clone | Earthquake Alerts - Weather and Climate | NBC News Clone | Solar Storm Warning - Weather and Climate | NBC News Clone | Hollywood Updates - Entertainment and Celebrity | NBC News Clone | Oscar Nominations 2025 - Entertainment and Celebrity | NBC News Clone | Grammy Awards 2025 - Entertainment and Celebrity | NBC News Clone | Netflix New Releases - Entertainment and Celebrity | NBC News Clone | Video Game Releases - Entertainment and Celebrity | NBC News Clone | Bestseller List - Entertainment and Celebrity | NBC News Clone | Government Transparency - Investigations and Analysis | NBC News Clone | Political Corruption - Investigations and Analysis | NBC News Clone | Big Tech Monopoly - Investigations and Analysis | NBC News Clone | Data Privacy Scandal - Investigations and Analysis | NBC News Clone | Community Stories - Local News and Communities | NBC News Clone | Nyc Mayor News - Local News and Communities | NBC News Clone | La Wildfires Update - Local News and Communities | NBC News Clone | Hurricane Preparedness - Local News and Communities | NBC News Clone